% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Haug:299476,
      author       = {A. J. Haug and N. Støer and H. Langseth and F. Siafarikas
                      and E. Botteri and R. T. Fortner$^*$ and K. Lindemann},
      title        = {{N}on-steroidal anti-inflammatory medication use and
                      endometrial cancer survival: {A} population-based
                      {N}orwegian cohort study.},
      journal      = {International journal of cancer},
      volume       = {157},
      number       = {2},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2025-00436},
      pages        = {277-287},
      year         = {2025},
      note         = {Volume157, Issue2, 15 July 2025, Pages 277-287},
      abstract     = {While nonsteroidal anti-inflammatory drugs (NSAIDs) have
                      been shown to improve survival in certain cancers, data in
                      patients with endometrial cancer (EC) is conflicting. This
                      study investigated use of aspirin and nonaspirin NSAIDs
                      (NA-NSAIDs) and EC-specific-and all-cause death. This
                      nationwide cohort study linked data from the Cancer Registry
                      of Norway with The Norwegian Prescription database. Patients
                      diagnosed with EC from 2004 to 2018 were included.
                      Post-diagnosis exposure to aspirin and NA-NSAIDs was defined
                      as ≥3 consecutive prescriptions ≥30 days after EC
                      diagnosis, with pre-diagnosis use as ≥2 filled
                      prescriptions <6 months prior to diagnosis. Follow-up
                      started 10 months after diagnosis. Hazard ratios for the
                      risk of death were calculated with multivariable
                      Cox-regression models. Our study population included 7751
                      individuals with EC, 685 $(9\%)$ were aspirin users and 620
                      $(8\%)$ were NA-NSAIDs users. The median follow-up time was
                      5.0 years, with 1518 $(20\%)$ deaths observed (n = 728
                      $(9\%)$ EC-specific). In multivariable analysis, aspirin use
                      was significantly associated with a $19\%$ higher risk of
                      all-cause death compared to non-users (HR = 1.19, $95\%$ CI
                      [1.01-1.41]). The association was stronger among combined
                      pre- and postdiagnosis use (HR = 1.35 [1.12-1.64]).
                      NA-NSAIDs use increased risk of cancer-related death (HR =
                      1.25 [0.99-1.58]) and there was a dose-response association
                      with significantly higher risk of cancer-specific death with
                      higher cumulative doses (HR = 1.33 [1.02-1.75]). We found a
                      higher risk of cancer-specific-and all-cause death among
                      patients that used aspirin and NA-NSAIDs after a diagnosis
                      of EC. Further studies on the biological mechanisms
                      underlying these associations are needed.},
      keywords     = {NSAIDS (Other) / aspirin (Other) / endometrial cancer
                      (Other) / survival (Other) / tertiary prevention (Other)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39992017},
      doi          = {10.1002/ijc.35363},
      url          = {https://inrepo02.dkfz.de/record/299476},
}